Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News

Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News

Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).

read more